China Digest: GP Capital leads $26m Series B in Baijiayun; TargetRx raises $14m

Baijiayun has secured 178 million yuan ($26 million) in a Series B round of financing led by existing investor GP Capital, while Shenzhen Targetrx has garnered nearly 100 million yuan ($14 million) from Hongtai Aplus.